Life sciences development company focusing on researching novel psychedelic compounds, developing and licensing psychedelic compounds the pharmaceutical and nutraceutical markets Halucenex Sciences Inc. has been granted Clinical Trial Authorization (CTA) by Health Canada.
This makes Halucenex one of the few psychedelics companies in Canada with clearance to start clinical trials utilizing psychedelic substances. Going forward, the company will now begin its phase 2 clinical trials to test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD)
Halucenex Sciences is a fully owned subsidiary of Canada based pharmaceutical company developing, producing and marketing a range of cannabis derived products for humans and animals Creso Pharma Ltd. (ASX: CPH) (OTCMKTS: COPHF).
“Securing Clinical Trial Authorization solidifies over 16 months of hard work and dedication from our team and positions Halucenex as one of very few Canadian companies with approval to commence a clinical trial utilizing psychedelic substances on mental health conditions,” said the company’s founder and CEO, Bill Fleming.
The company submitted its application on January which was subject to a 30-day review process by Health Canada before the approval was finally granted.